2 Information about tirzepatide

Marketing authorisation indication

2.1 Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

  • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

  • in addition to other medicinal products for the treatment of diabetes'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for tirzepatide.


2.3 The list price of tirzepatide (Mounjaro) is £23 per weekly dose for the 2.5 mg and 5 mg doses, £26.75 per weekly dose for the 7.5 mg and 10 mg doses, and £30.50 per weekly dose for the 12.5 mg and 15 mg doses (excluding VAT; company communication).

  • National Institute for Health and Care Excellence (NICE)